Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Seksik

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Crohn'S & Colitis|January 21, 2014
Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel diseaseS Rajca, P Seksik, A Bourrier, et al.
Gut|January 14, 2003
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colonP Seksik, L Rigottier-Gois, G Gramet, et al.
Alimentary Pharmacology & Therapeutics|September 12, 2006
Review article: the role of bacteria in onset and perpetuation of inflammatory bowel diseaseP Seksik, H Sokol, P Lepage, et al.
Alimentary Pharmacology & Therapeutics|September 11, 2015
The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximabG Dumitrescu, A Amiot, P Seksik, et al.
Journal of Crohn'S & Colitis|December 31, 2014
Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's diseaseC Gagniere, L Beaugerie, B Pariente, et al.
Endoscopy|July 13, 2005
Video capsule endoscopy for investigation of obscure gastrointestinal bleeding: feasibility, results, and interobserver agreementA De Leusse, B Landi, J Edery, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2016
Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's diseaseJ Cosnes, H Sokol, A Bourrier, et al.
Gastroenterologie Clinique Et Biologique|August 30, 2000
[Efficacity of treatment with lamivudine in two patients with severe reactivation of hepatitis B after withdrawal of chemotherapy]P Seksik, S Nahon, B Lesgourgues, et al.
Inflammatory Bowel Diseases|February 25, 2009
Low counts of Faecalibacterium prausnitzii in colitis microbiotaH Sokol, P Seksik, J P Furet, et al.
Gut|December 3, 2015
Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgeryS Mondot, P Lepage, P Seksik, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Crohn'S & Colitis|January 21, 2014
Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel diseaseS Rajca, P Seksik, A Bourrier, et al.
Gut|January 14, 2003
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colonP Seksik, L Rigottier-Gois, G Gramet, et al.
Alimentary Pharmacology & Therapeutics|September 12, 2006
Review article: the role of bacteria in onset and perpetuation of inflammatory bowel diseaseP Seksik, H Sokol, P Lepage, et al.
Alimentary Pharmacology & Therapeutics|September 11, 2015
The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximabG Dumitrescu, A Amiot, P Seksik, et al.
Journal of Crohn'S & Colitis|December 31, 2014
Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's diseaseC Gagniere, L Beaugerie, B Pariente, et al.
Endoscopy|July 13, 2005
Video capsule endoscopy for investigation of obscure gastrointestinal bleeding: feasibility, results, and interobserver agreementA De Leusse, B Landi, J Edery, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2016
Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's diseaseJ Cosnes, H Sokol, A Bourrier, et al.
Gastroenterologie Clinique Et Biologique|August 30, 2000
[Efficacity of treatment with lamivudine in two patients with severe reactivation of hepatitis B after withdrawal of chemotherapy]P Seksik, S Nahon, B Lesgourgues, et al.
Inflammatory Bowel Diseases|February 25, 2009
Low counts of Faecalibacterium prausnitzii in colitis microbiotaH Sokol, P Seksik, J P Furet, et al.
Gut|December 3, 2015
Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgeryS Mondot, P Lepage, P Seksik, et al.
Pageof 4